A report issued by the Pharmaceutical Research and Manufacturers of America (PhRMA) and the ALS Association detailed the development of new medicines in the industry, including more than 560 treatments for patients with rare diseases. The report, titled “Medicines in Development for Rare Diseases,” details new medicines currently in development, including therapies for multiple myeloma, cystic fibrosis, amyotrophic lateral sclerosis (ALS) and enzyme deficiency disorders. Medicines currently in development include 151 for rare cancers and 82 for blood cancers, 148 for genetic disorders like cystic fibrosis and spinal muscular atrophy, 38 for neurological disorders, including ALS and seizures, 31 for infectious diseases, and 25 for autoimmune diseases. The report provides information on the medicines in development for rare diseases by therapeutic area and in which stage of development the drug is in currently. For a complete list of the 566 medicines in development, click here.
In related news, a report by the IMS Institute for Healthcare Informatics showed that payers in the USA spent US$425 billion in 2015, an increase of more than 12% from 2014. The increased drug expenditure was due primarily to the launch of novel and innovative drugs, especially in the area of oncology.